Anne Moon
Nessuna posizione attualmente
Profilo
Anne Moon is the founder of SillaJen Biotherapeutics, Inc. She previously worked as the Vice President of Project Management at Aduro BioTech, Inc. and as the Senior Vice President at Tempest Therapeutics, Inc. She completed her undergraduate degree at Harvard University and her doctorate at the University of California, Berkeley.
Precedenti posizioni note di Anne Moon
| Società | Posizione | Fine |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2023 |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Fondatore | 01/01/2014 |
| CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formazione di Anne Moon
| Harvard University | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Esperienze
Posizioni ricoperte
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Borsa valori
- Insiders
- Anne Moon
